Bill Haddad

Akebia met with the FDA in November to discuss its appeal and subsequently received a request for additional clarifying information from the Office of New Drugs, Center for Drug Evaluation and Research, which is deciding

atai Life Sciences Announces Perception Neuroscience's Phase 2a ... - Benzinga

USA ISM Non-Manufacturing PMI For December 49.6 Vs 55.0 Est ... - Benzinga

T-Mobile shares are trading lower after MoffetNathanson ... - Benzinga

Frequency Therapeutics shares are trading lower after the company ... - Benzinga

Marathon Digital shares are trading higher after Soros Fund ... - Benzinga

Union Pacific shares are trading higher after B of A Securities ... - Benzinga

Azeliragon, previously known as TTP488, is an orally active, small molecule, antagonist of the receptor for advanced glycation end products (RAGE) licensed by Cantex from vTv Therapeutics Inc. (NASDAQ:VTVT). vTv

Core Durable Goods Orders (MoM) (Jan) 0.7% vs 0.1% Est. - SPDR ... - Benzinga

CrowdStrike shares are trading higher after Morgan Stanley raised ... - Benzinga

Manchester United shares are trading lower following an article from ... - Benzinga

Reata Pharmaceuticals shares are trading lower following reports ... - Benzinga

Zillow shares are trading higher after JP Morgan initiated coverage ... - Benzinga

Merck Announces Phase 3 KEYNOTE-789 Did Not Meet Dual ... - Benzinga

US Crude Oil Inventories 6.203M Barrel Build vs 0.440M Barrel ... - Benzinga

Salesforce shares are trading higher after the company reported ... - Benzinga

Aptorum Group Announces Completion Of Pre-IND Discussions ... - Benzinga

Continuing Jobless Claims 1.655M vs 1.665M Est. - SPDR S&P 500 ... - Benzinga

Major indices are higher going into the close following strong ... - Benzinga

Kroger shares are trading higher after the company reported better ... - Benzinga